Product Information
Registration Status: ActiveURISPAS 200 TABLET 200mg is approved to be sold in Singapore with effective from 2002-01-07. It is marketed by DCH AURIGA SINGAPORE, with the registration number of SIN12007P.
This product contains Flavoxate 200mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
Indication
For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
Mechanism of Action
Flavoxate acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.
Pharmacokinetics
- Absorption
- Well absorbed from gastrointestinal tract.
- Distribution
- Metabolism
- Elimination
Toxicity
The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.
Active Ingredient/Synonyms
2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate | 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate | 2-Piperidinoethyl 3-methylflavone-8-carboxylate | beta-Piperidinoethyl 3-methylflavone-8-carboxylate | Flavoxate | Flavoxate HCI | Flavoxato | Flavoxatum | Flavoxate |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.